

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS	42	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,

CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
 AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:40:41 ON 03 FEB 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:40:49 ON 03 FEB 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES:	2 FEB 2003	HIGHEST RN 484639-64-7
DICTIONARY FILE UPDATES:	2 FEB 2003	HIGHEST RN 484639-64-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>



=> .....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2076 AND 2127

L1 SCREEN CREATED

=> screen 1918



chain nodes :

16 17 18 19 20 21 28 29 30 31 32 33 34 35 36 37 39 40 47

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 22 23 24 25 26 27

chain bonds :

10-20 11-16 12-17 13-18 14-19 20-21 21-25 22-28 23-34 24-35 26-32 27-33 28-29  
28-36 28-37 29-30 29-31 31-47

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 8-11 9-10 9-14 11-12 12-13 13-14  
22-23 22-27 23-24 24-25 25-26 26-27

exact/norm bonds :

4-7 5-10 7-8 9-10 10-20 11-16 12-17 13-18 14-19 20-21 21-25 22-28 23-34 24-35  
26-32 27-33 28-29 28-36 28-37 29-30 29-31 31-47

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-11 9-14 11-12 12-13 13-14 22-23 22-27 23-24  
24-25 25-26 26-27

G1:O,S

G2:OH,CN,NO2,X,H,Ak

G3:H,Ak



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS  
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS 29:CLASS 30:CLASS  
31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 39:CLASS 40:CLASS  
44:CLASS 45:CLASS 47:CLASS

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10067096.str



chain nodes :

16 17 18 19 20 21 28 29 30 31 32 33 34 35 36 37 39 40 47

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 22 23 24 25 26 27

chain bonds :

10-20 11-16 12-17 13-18 14-19 20-21 21-25 22-28 23-34 24-35 26-32 27-33

28-29 28-36 28-37 29-30 29-31 31-47

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 8-11 9-10 9-14 11-12 12-13

13-14 22-23 22-27 23-24 24-25 25-26 26-27

exact/norm bonds :

4-7 5-10 7-8 9-10 10-20 11-16 12-17 13-18 14-19 20-21 21-25 22-28 23-34

24-35 26-32 27-33 28-29 28-36 28-37 29-30 29-31 31-47

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-11 9-14 11-12 12-13 13-14 22-23 22-27

23-24 24-25 25-26 26-27

G1:O,S

G2:OH,CN,NO2,X,H,Ak

G3:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS  
20:CLASS 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS  
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS  
37:CLASS 39:CLASS 40:CLASS 44:CLASS 45:CLASS 47:CLASS

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

=> d l4

L4 HAS NO ANSWERS

L1 SCR 2076 AND 2127

L2 SCR 1918

L3 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> d l3

L3 HAS NO ANSWERS

L3 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 09:41:52 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED 14 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 56 TO 504

PROJECTED ANSWERS: 22 TO 418

L5 11 SEA SSS SAM L3 AND L1 NOT L2


=> d scan

L5 11 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)-(9CI)

MF C26 H27 N O5 . H3 N

Rotation (-).



● NH<sub>3</sub>

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 14 sss full

FULL SEARCH INITIATED 09:42:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 270 TO ITERATE

100.0% PROCESSED 270 ITERATIONS

198 ANSWERS

SEARCH TIME: 00.00.01

L6 198 SEA SSS FUL L3 AND L1 NOT L2

=> file caold ca

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.95

149.16

FILE 'CAOLD' ENTERED AT 09:42:45 ON 03 FEB 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CA' ENTERED AT 09:42:45 ON 03 FEB 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 16

L7 10 L6

=> sort 17 py

SORT ENTIRE ANSWER SET? (Y)/N:.

PROCESSING COMPLETED FOR L7

L8 10 SORT L7 PY

=> d 18 cbib pi hitstr 1-10

L8 ANSWER 1 OF 10 CA COPYRIGHT 2003 ACS

133:310141 Preparation of novel polymorphic forms of an antidiabetic agent.

Gaddam, Om Reddy; Potlapally, Rajendra Kumar; Sirisilla, Raju;

Krishnamurthy, Vyas; Dharmaraja, Sreenivasa Rao; Mamaillapally, Ramabhadra

Sarma (Reddy's Research Foundation, India; Reddy-Cheminor, Inc.). PCT

Int. Appl. WO 2000063193 A1 20001026, 95 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US10309 20000417. PRIORITY: WO 1999-IB681 19990416; DK 1999-536 19990420.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000063193	A1	20001026	WO 2000-US10309	20000417
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2000063191	A1	20001026	WO 1999-IB681	19990416
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

IT **264268-75-9P**  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of novel polymorphic forms of arginine salt of antidiabetic agent [(phenoxazinyl)ethoxy]phenyl]ethoxypropanoic acid)

RN 264268-75-9 CA


CN L-Arginine, mono[( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2

CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



L8 ANSWER 2 OF 10 CA COPYRIGHT 2003 ACS

133:310140 Preparation of novel polymorphic forms of an antidiabetic agent.

Gaddam, Om Reddy; Potlapally, Rajender Kumar; Sirisilla, Raju; Krishnamurthi, Vyas; Dharmaraja, Sreenivasa Rao; Mamillapalli, Ramabhadra Sarma (India). PCT Int. Appl. WO 2000063192 A1 20001026, 95 pp.

DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG.

(English). CODEN: PIXXD2. APPLICATION: WO 2000-IB470 20000417.

PRIORITY: IN 1999-MA405 19990412; WO 1999-IB681 19990416.

PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2000063192	A1	20001026	WO 2000-IB470	20000417
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	WO 2000063191	A1	20001026	WO 1999-IB681	19990416
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1171430	A1	20020116	EP 2000-917222	20000417
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	NO 2001005016	A	20011211	NO 2001-5016	20011015

IT 264268-75-9P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(preparation of novel polymorphic forms of arginine salt of antidiabetic agent [(phenoxazinyl)ethoxy]phenyl]ethoxypropanoic acid)

RN 264268-75-9 CA

CN L-Arginine, mono[(αS)-α-ethoxy-4-[2-(10H-phenoxazin-10-




yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




L8 ANSWER 3 OF 10 CA COPYRIGHT 2003 ACS

133:310139 Preparation of novel polymorphic forms of an antidiabetic agent.  
Gaddam, Om Reddy; Potlapally, Rajender Kumar; Sirisilla, Raju;  
Krishnamurthi, Vyas; Dharmaraja, Sreenivasa Rao; Mamillapalli, Ramabhadra  
Sarma (Reddy's Research Foundation, India). PCT Int. Appl. WO 2000063191  
A1 20001026, 81 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA,  
BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,  
KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK,  
ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD,  
TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-IB681 19990416.  
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2000063191	A1	20001026	WO 1999-IB681	19990416
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,			

MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
AU 9929536 A1 20001102 AU 1999-29536 19990416  
WO 2000063189 A1 20001026 WO 2000-DK188 20000417  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,  
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,  
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
WO 2000063192 A1 20001026 WO 2000-IB470 20000417  
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,  
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
WO 2000063193 A1 20001026 WO 2000-US10309 20000417  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,  
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
EP 1171430 A1 20020116 EP 2000-917222 20000417  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO  
NO 2001005016 A 20011211 NO 2001-5016 20011015  
US 2002173647 A1 20021121 US 2002-142857 20020509  
US 2003004341 A1 20030102 US 2002-209567 20020730  
IT **264268-75-9P**  
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(preparation of novel polymorphic forms of arginine salt of antidiabetic  
agent [[(phenoxazinyl)ethoxy]phenyl]ethoxypropanoic acid)  
RN 264268-75-9 CA  
CN L-Arginine, mono[( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-  
yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
CM 1  
CRN 222834-30-2  
CMF C25 H25 N O5  
Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



L8 ANSWER 4 OF 10 CA COPYRIGHT 2003 ACS

133:310138 Preparation of crystalline R-guanidines, arginine or L-arginine (2S)-2-ethoxy-3-[4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl]propanoate.

Ebdrup, Soren; Lugstein, Petra Christine (Novo Nordisk A/S, Den.; Reddy's Research Foundation). PCT Int. Appl. WO 2000063189 A1 20001026, 34 pp.

DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-DK188 20000417.

PRIORITY: WO 1999-IB681 19990416; DK 1999-536 19990420.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063189	A1	20001026	WO 2000-DK188	20000417
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2000063191	A1	20001026	WO 1999-IB681	19990416
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,			

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,  
 MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT 264268-75-9P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of crystalline arginine  
 ethoxy[(phenoxazinyl)ethoxy]phenyl]propanoa  
 te)

RN 264268-75-9 CA


CN L-Arginine, mono[( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-  
 yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2

CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



L8 ANSWER 5 OF 10 CA COPYRIGHT 2003 ACS

133:193155 Preparation of  $\beta$ -aryl- $\alpha$ -oxy substituted alkylcarboxylic  
 acids as hypolipidemic, antihyperglycemic, antiobesity, and  
 hypocholesterolemic agents. Lohray, Braj Bhushan; Lohray, Vidya Bhushan;  
 Ashok, Channaveerappa Bajji; Shivaramayya, Kalchar; Paraselli, Bheema Rao;  
 Gurram, Ranga Madhavan; Rajagopalan, Ramanujam; Rajan, Chakrabarti  
 (Dr.Reddy's Research Foundation, India). PCT Int. Appl. WO 2000050414 A1

20000831, 116 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG.

(English). CODEN: PIXXD2. APPLICATION: WO 1999-IB683 19990416.

PRIORITY: US 1999-257104 19990224.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000050414	A1	20000831	WO 1999-IB683	19990416
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6440961	B1	20020827	US 1999-257104	19990224
AU 9929537	A1	20000914	AU 1999-29537	19990416
EP 1155006	A1	20011121	EP 1999-910638	19990416
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 9917155	A	20020423	BR 1999-17155	19990416
JP 2002537390	T2	20021105	JP 2000-600997	19990416
NO 2001004102	A	20011024	NO 2001-4102	20010823

IT 264266-31-1P 264266-33-3P 264266-34-4P  
 264266-35-5P 264266-37-7P 264266-38-8P  
 264266-46-8P 264266-47-9P 264266-48-0P  
 264266-49-1P 264266-51-5P 264266-52-6P  
 264266-60-6P 264266-61-7P 264266-62-8P  
 264266-63-9P 264266-65-1P 264266-66-2P  
 264266-74-2P 264266-75-3P 264266-76-4P  
 264266-77-5P 264266-79-7P 264266-80-0P  
 264266-87-7P 264266-88-8P 264266-90-2P  
 264266-91-3P 264266-93-5P 264266-94-6P  
 264267-01-8P 264267-02-9P 264267-03-0P  
 264267-05-2P 264267-07-4P 264267-08-5P  
 264268-46-4P 264268-47-5P 264268-48-6P  
 264268-49-7P 264268-51-1P 264268-52-2P  
 264268-60-2P 264268-61-3P 264268-62-4P  
 264268-63-5P 264268-65-7P 264268-67-9P  
 264268-74-8P 264268-75-9P 264268-77-1P  
 264268-78-2P 264268-80-6P 264268-81-7P  
 264268-92-0P 264268-93-1P 264268-94-2P  
 264268-95-3P 264268-97-5P 264268-98-6P  
 264269-05-8P 264269-06-9P 264269-07-0P  
 264269-08-1P 264269-10-5P 264269-11-6P  
 264269-18-3P 264269-19-4P 264269-20-7P  
 264269-21-8P 264269-23-0P 264269-24-1P  
 264270-09-9P 264270-11-3P 264270-13-5P  
 264270-14-6P 264270-16-8P 264270-17-9P  
 264270-24-8P 264270-25-9P 264270-26-0P  
 264270-27-1P 264270-29-3P 264270-30-6P  
 264270-37-3P 264270-39-5P 264270-41-9P  
 264270-43-1P 264270-45-3P 264270-46-4P  
 264270-52-2P 264270-53-3P 264270-54-4P  
 264270-55-5P 264270-57-7P 264270-58-8P  
 264270-65-7P 264270-66-8P 264270-67-9P  
 264270-68-0P 264270-70-4P 264270-71-5P

264270-78-2P 264270-79-3P 264270-81-7P  
 264270-83-9P 264270-85-1P 264270-87-3P  
 264270-99-7P 264271-01-4P 264271-03-6P  
 264271-05-8P 264271-08-1P 264271-10-5P  
 264271-18-3P 264271-19-4P 264271-20-7P  
 264271-21-8P 264271-23-0P 264271-24-1P  
 264271-31-0P 264271-32-1P 264271-33-2P  
 264271-34-3P 264271-36-5P 264271-37-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of  $\beta$ -aryl- $\alpha$ -oxy substituted alkylcarboxylic acids as hypolipidemic, antihyperglycemic, antiobesity, and hypocholesterolemic agents)


RN 264266-31-1 CA

CN L-Lysine, mono[ $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5

CMF C25 H25 N O4 S




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-33-3 CA

CN L-Arginine, mono[ $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-17-5  
CMF C25 H25 N O4 S



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 264266-34-4 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-17-5  
CMF C25 H25 N O4 S



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264266-35-5 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5

CMF C25 H25 N O4 S





CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264266-37-7 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-36-6


CMF C25 H24 N O4 S



CM 2


CRN 62-49-7

CMF C5 H14 N O




RN 264266-38-8 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264266-46-8 CA  
 CN L-Lysine, mono[(+)-α-ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-51-7  
 CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2  
 CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-47-9 CA  
CN L-Arginine, mono[(+)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7  
CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264266-48-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7  
CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264266-49-1 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7

CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264266-51-5 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-50-4  
 CMF C25 H24 N O4 S

Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264266-52-6 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




●  $\text{NH}_3$

RN 264266-60-6 CA  
CN L-Lysine, mono[(-)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-61-7 CA  
CN L-Arginine, mono[(-)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264266-62-8 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9


CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 113-00-8  
CMF C H5 N3




RN 264266-63-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-53-9  
CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 111-42-2  
CMF C4 H11 N O2




RN 264266-65-1 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-64-0  
CMF C25 H24 N O4 S

Rotation (-).





CM 2

CRN 62-49-7


CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264266-66-2 CA

CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● NH<sub>3</sub>


RN 264266-74-2 CA

CN L-Lysine, mono[α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0

CMF C26 H27 N O4 S




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-75-3 CA

CN L-Arginine, mono[α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0

CMF C26 H27 N O4 S




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264266-76-4 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0


CMF C26 H27 N O4 S



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264266-77-5 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0

CMF C26 H27 N O4 S



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264266-79-7 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-78-6


CMF C26 H26 N O4 S



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264266-80-0 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264266-87-7 CA  
 CN L-Lysine, mono[(+)-α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-55-1  
 CMF C26 H27 N O4 S


Rotation (+).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-88-8 CA  
CN L-Arginine, mono[(+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-55-1  
CMF C26 H27 N O4 S


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264266-90-2 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-55-1  
CMF C26 H27 N O4 S


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264266-91-3 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-55-1

CMF C26 H27 N O4 S

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2



HO-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>-CH<sub>2</sub>-OH

RN 264266-93-5 CA


CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)-α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-92-4

CMF C26 H26 N O4 S

Rotation (+).



CM 2

CRN 62-49-7


CMF C5 H14 N O

Me<sub>3</sub><sup>+</sup>N-CH<sub>2</sub>-CH<sub>2</sub>-OH

RN 264266-94-6 CA

CN Benzenepropanoic acid, α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● NH<sub>3</sub>

RN 264267-01-8 CA  
 CN L-Lysine, mono[(-)-α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-56-2  
 CMF C26 H27 N O4 S


Rotation (-).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 264267-02-9 CA


CN L-Arginine, mono[(-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-56-2

CMF C26 H27 N O4 S

Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264267-03-0 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-56-2

CMF C26 H27 N O4 S


Rotation (-).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264267-05-2 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-56-2

CMF C26 H27 N O4 S


Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2



RN 264267-07-4 CA


CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264267-06-3

CMF C26 H26 N O4 S


Rotation (-).



CM 2

CRN 62-49-7


CMF C5 H14 N O



RN 264267-08-5 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




● NH<sub>3</sub>

RN 264268-46-4 CA  
 CN L-Lysine, mono[α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1  
 CMF C25 H25 N O5



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 264268-47-5 CA  
 CN L-Arginine, mono[α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1  
 CMF C25 H25 N O5



CM 2

CRN 74-79-3  
 CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 264268-48-6 CA  
 CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1  
 CMF C25 H25 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264268-49-7 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-21-1

CMF C25 H25 N O5





CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264268-51-1 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264268-50-0


CMF C25 H24 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O




RN 264268-52-2 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264268-60-2 CA  
 CN L-Lysine, mono[(αR)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-29-9  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2  
 CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264268-61-3 CA  
CN L-Arginine, mono[( $\alpha$ R)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264268-62-4 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264268-63-5 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9

CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2



RN 264268-65-7 CA


CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (αR)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 264268-64-6

CMF C25 H24 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 62-49-7


CMF C5 H14 N O



RN 264268-67-9 CA

CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● NH<sub>3</sub>

RN 264268-74-8 CA  
 CN L-Lysine, mono[(αS)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
 CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264268-75-9 CA

CN L-Arginine, mono[( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264268-77-1 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264268-78-2 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2

CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2






RN 264268-80-6 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (αS)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 264268-79-3  
 CMF C25 H24 N O5

Absolute stereochemistry. Rotation (-).





CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264268-81-7 CA  
 CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 264268-92-0 CA  
 CN L-Lysine, mono[α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-67-5  
 CMF C26 H27 N O5



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 264268-93-1 CA  
 CN L-Arginine, mono[ $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-67-5  
 CMF C26 H27 N O5



CM 2

CRN 74-79-3  
 CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 264268-94-2 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-67-5  
 CMF C26 H27 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264268-95-3 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-67-5

CMF C26 H27 N O5



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264268-97-5 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 264268-96-4


CMF C26 H26 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264268-98-6 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264269-05-8 CA  
 CN L-Lysine, mono[(+)-α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-68-6  
 CMF C26 H27 N O5


Rotation (+).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264269-06-9 CA  
CN L-Arginine, mono[(+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-68-6  
CMF C26 H27 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264269-07-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-68-6  
CMF C26 H27 N O5


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264269-08-1 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-68-6

CMF C26 H27 N O5

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2






RN 264269-10-5 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 264269-09-2  
 CMF C26 H26 N O5

Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264269-11-6 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● NH<sub>3</sub>

RN 264269-18-3 CA  
 CN L-Lysine, mono[(-)-α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7  
 CMF C26 H27 N O5


Rotation (-).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264269-19-4 CA

CN L-Arginine, mono[(-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7  
CMF C26 H27 N O5


Rotation (-).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264269-20-7 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7  
CMF C26 H27 N O5


Rotation (-).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264269-21-8 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7

CMF C26 H27 N O5

Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264269-23-0 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 264269-22-9  
 CMF C26 H26 N O5

Rotation (-).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264269-24-1 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




● NH<sub>3</sub>

RN 264270-09-9 CA  
 CN L-Lysine, mono[α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-23-3  
 CMF C23 H21 N O5




CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-11-3 CA  
 CN L-Arginine, mono[α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-23-3  
 CMF C23 H21 N O5




CM 2  
 CRN 74-79-3  
 CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264270-13-5 CA  
 CN Benzenepropanoic acid, α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-23-3  
 CMF C23 H21 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264270-14-6 CA

CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-23-3

CMF C23 H21 N O5






CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264270-16-8 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-15-7


CMF C23 H20 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264270-17-9 CA

CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, monoammonium salt (9CI) (CA INDEX NAME)




RN 264270-24-8 CA  
 CN L-Lysine, mono[(+)-α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-91-5  
 CMF C23 H21 N O5


Rotation (+).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-25-9 CA  
CN L-Arginine, mono[(+)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-91-5  
CMF C23 H21 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264270-26-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-91-5  
CMF C23 H21 N O5


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264270-27-1 CA


CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-91-5

CMF C23 H21 N O5

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264270-29-3 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-28-2  
 CMF C23 H20 N O5

Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264270-30-6 CA  
 CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, monoammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




●  $\text{NH}_3$

RN 264270-37-3 CA  
CN L-Lysine, mono[(-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-94-8  
CMF C23 H21 N O5


Rotation (-).



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-39-5 CA  
CN L-Arginine, mono[(-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-94-8  
CMF C23 H21 N O5

Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264270-41-9 CA


CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-94-8


CMF C23 H21 N O5

Rotation (-).



CM 2

CRN 113-00-8  
CMF C H5 N3




RN 264270-43-1 CA  
CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-  
, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-94-8  
CMF C23 H21 N O5

Rotation (-).



CM 2

CRN 111-42-2  
CMF C4 H11 N O2




RN 264270-45-3 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-44-2  
CMF C23 H20 N O5

Rotation (-).






CM 2

CRN 62-49-7


CMF C5 H14 N O



RN 264270-46-4 CA

CN Benzenepropanoic acid, α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-  
, monoammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 264270-52-2 CA

CN L-Lysine, mono[α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4

CMF C27 H29 N O5




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-53-3 CA

CN L-Arginine, mono[α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4

CMF C27 H29 N O5




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264270-54-4 CA

CN Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4


CMF C27 H29 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264270-55-5 CA

CN Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4

CMF C27 H29 N O5



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264270-57-7 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-56-6


CMF C27 H28 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264270-58-8 CA

CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264270-65-7 CA  
 CN L-Lysine, mono[ (+)-α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0  
 CMF C27 H29 N O5


Rotation (+).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-66-8 CA  
CN L-Arginine, mono[(+)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0  
CMF C27 H29 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264270-67-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0  
CMF C27 H29 N O5


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264270-68-0 CA


CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0

CMF C27 H29 N O5

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2






RN 264270-70-4 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-69-1  
 CMF C27 H28 N O5

Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264270-71-5 CA  
 CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




●  $\text{NH}_3$

RN 264270-78-2 CA  
CN L-Lysine, mono[(-)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2  
CMF C27 H29 N O5


Rotation (-).



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-79-3 CA  
CN L-Arginine, mono[(-)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2  
CMF C27 H29 N O5

Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264270-81-7 CA


CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2


CMF C27 H29 N O5

Rotation (-).



CM 2

CRN 113-00-8  
CMF C H5 N3




RN 264270-83-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2  
CMF C27 H29 N O5

Rotation (-).



CM 2

CRN 111-42-2  
CMF C4 H11 N O2




RN 264270-85-1 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-84-0  
CMF C27 H28 N O5

Rotation (-).



CM 2

CRN 62-49-7


CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264270-87-3 CA

CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



●  $\text{NH}_3$


RN 264270-99-7 CA

CN L-Lysine, mono[ $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6

CMF C29 H33 N O5




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264271-01-4 CA

CN L-Arginine, mono[α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6

CMF C29 H33 N O5




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264271-03-6 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6


CMF C29 H33 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264271-05-8 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6

CMF C29 H33 N O5





CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264271-08-1 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264271-07-0


CMF C29 H32 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264271-10-5 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264271-18-3 CA  
 CN L-Lysine, mono[ (+)-α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3  
 CMF C29 H33 N O5


Rotation (+).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264271-19-4 CA  
CN L-Arginine, mono[(+)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3  
CMF C29 H33 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264271-20-7 CA  
CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3  
CMF C29 H33 N O5


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264271-21-8 CA


CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3

CMF C29 H33 N O5

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2



RN 264271-23-0 CA


CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264271-22-9

CMF C29 H32 N O5


Rotation (+).



CM 2

CRN 62-49-7


CMF C5 H14 N O



RN 264271-24-1 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● NH<sub>3</sub>

RN 264271-31-0 CA  
 CN L-Lysine, mono[(-)-α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9  
 CMF C29 H33 N O5


Rotation (-).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264271-32-1 CA

CN L-Arginine, mono[(-)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9  
CMF C29 H33 N O5


Rotation (-).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264271-33-2 CA  
CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9  
CMF C29 H33 N O5


Rotation (-).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264271-34-3 CA


CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9

CMF C29 H33 N O5

Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2






RN 264271-36-5 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 264271-35-4  
 CMF C29 H32 N O5

Rotation (-).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264271-37-6 CA  
 CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● NH<sub>3</sub>

L8 ANSWER 6 OF 10 CA COPYRIGHT 2003 ACS

132:293769 Preparation of 4-(phenothiazinoalkoxy)phenylpropanoates and analogs as peroxisome proliferator-activated receptor agonists. Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Bajji, Ashok Channaveerappa; Kalchar, Shivaramayya; Ramanujam, Rajagopalan; Chakrabarti, Ranjan (Redd's Research Foundation, India; Reddy-Cheminor, Inc.). U.S. US 6054453 A 20000425, 30 pp. (English). CODEN: USXXAM. APPLICATION: US 1998-12585 19980123. PRIORITY: IN 1997-MA2416 19971027.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6054453	A	20000425	US 1998-12585	19980123
	US 6440961	B1	20020827	US 1999-257104	19990224
	US 2002077320	A1	20020620	US 2001-7109	20011206
IT	264266-31-1P	264266-33-3P	264266-34-4P		
	264266-35-5P	264266-37-7P	264266-38-8P		
	264266-46-8P	264266-47-9P	264266-48-0P		
	264266-49-1P	264266-51-5P	264266-52-6P		
	264266-60-6P	264266-61-7P	264266-62-8P		
	264266-63-9P	264266-65-1P	264266-66-2P		
	264266-74-2P	264266-75-3P	264266-76-4P		
	264266-77-5P	264266-79-7P	264266-80-0P		
	264266-87-7P	264266-88-8P	264266-90-2P		
	264266-91-3P	264266-93-5P	264266-94-6P		
	264267-01-8P	264267-02-9P	264267-03-0P		
	264267-05-2P	264267-07-4P	264267-08-5P		
	264268-46-4P	264268-47-5P	264268-48-6P		
	264268-49-7P	264268-51-1P	264268-52-2P		
	264268-60-2P	264268-61-3P	264268-62-4P		
	264268-63-5P	264268-65-7P	264268-67-9P		
	264268-74-8P	264268-75-9P	264268-77-1P		
	264268-78-2P	264268-80-6P	264268-81-7P		
	264268-92-0P	264268-93-1P	264268-94-2P		
	264268-95-3P	264268-97-5P	264268-98-6P		
	264269-05-8P	264269-06-9P	264269-07-0P		
	264269-08-1P	264269-10-5P	264269-11-6P		
	264269-18-3P	264269-19-4P	264269-20-7P		
	264269-21-8P	264269-23-0P	264269-24-1P		
	264270-09-9P	264270-11-3P	264270-13-5P		
	264270-14-6P	264270-16-8P	264270-17-9P		
	264270-24-8P	264270-25-9P	264270-26-0P		
	264270-27-1P	264270-29-3P	264270-30-6P		

264270-37-3P 264270-39-5P 264270-41-9P  
 264270-43-1P 264270-45-3P 264270-46-4P  
 264270-52-2P 264270-53-3P 264270-54-4P  
 264270-55-5P 264270-57-7P 264270-58-8P  
 264270-65-7P 264270-66-8P 264270-67-9P  
 264270-68-0P 264270-70-4P 264270-71-5P  
 264270-78-2P 264270-79-3P 264270-81-7P  
 264270-83-9P 264270-85-1P 264270-87-3P  
 264270-99-7P 264271-01-4P 264271-03-6P  
 264271-05-8P 264271-08-1P 264271-10-5P  
 264271-18-3P 264271-19-4P 264271-20-7P  
 264271-21-8P 264271-23-0P 264271-24-1P  
 264271-31-0P 264271-32-1P 264271-33-2P  
 264271-34-3P 264271-36-5P 264271-37-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-(phenothiazinoalkoxy)phenylpropanoates and analogs as peroxisome proliferator-activated receptor agonists)


RN 264266-31-1 CA

CN L-Lysine, mono[α-ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5

CMF C25 H25 N O4 S




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 264266-33-3 CA  
CN L-Arginine, mono[α-ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-17-5  
CMF C25 H25 N O4 S



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 264266-34-4 CA  
CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-17-5  
CMF C25 H25 N O4 S



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264266-35-5 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5

CMF C25 H25 N O4 S



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264266-37-7 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-36-6


CMF C25 H24 N O4 S



CM 2


CRN 62-49-7

CMF C5 H14 N O




RN 264266-38-8 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264266-46-8 CA  
 CN L-Lysine, mono[(+)-α-ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-51-7  
 CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2  
 CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-47-9 CA  
CN L-Arginine, mono[(+)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7  
CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264266-48-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7  
CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).






CM 2

CRN 113-00-8

CMF C H5 N3



RN 264266-49-1 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7

CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264266-51-5 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-50-4  
 CMF C25 H24 N O4 S

Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264266-52-6 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




●  $\text{NH}_3$

RN 264266-60-6 CA  
CN L-Lysine, mono[(-)-α-ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-61-7 CA  
CN L-Arginine, mono[(-)-α-ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264266-62-8 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9


CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 113-00-8  
CMF C H5 N3




RN 264266-63-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 111-42-2  
CMF C4 H11 N O2




RN 264266-65-1 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-64-0  
CMF C25 H24 N O4 S

Rotation (-).



CM 2

CRN 62-49-7


CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264266-66-2 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● NH<sub>3</sub>


RN 264266-74-2 CA

CN L-Lysine, mono[ $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0

CMF C26 H27 N O4 S




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-75-3 CA

CN L-Arginine, mono[α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0

CMF C26 H27 N O4 S




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264266-76-4 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0

CMF C26 H27 N O4 S






CM 2

CRN 113-00-8

CMF C H5 N3




RN 264266-77-5 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1)  
(9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0

CMF C26 H27 N O4 S



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264266-79-7 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-78-6


CMF C26 H26 N O4 S



CM 2


CRN 62-49-7

CMF C5 H14 N O




RN 264266-80-0 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264266-87-7 CA  
 CN L-Lysine, mono[(+)-α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-55-1  
 CMF C26 H27 N O4 S

Rotation (+).



CM 2  
 CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-88-8 CA  
CN L-Arginine, mono[(+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-55-1  
CMF C26 H27 N O4 S


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264266-90-2 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-55-1  
CMF C26 H27 N O4 S


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264266-91-3 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-55-1

CMF C26 H27 N O4 S

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2

HO-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>-CH<sub>2</sub>-OH

RN 264266-93-5 CA


CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)-α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-92-4

CMF C26 H26 N O4 S

Rotation (+).



CM 2

CRN 62-49-7


CMF C5 H14 N O

Me<sub>3</sub><sup>+</sup>N-CH<sub>2</sub>-CH<sub>2</sub>-OH

RN 264266-94-6 CA

CN Benzenepropanoic acid, α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● NH<sub>3</sub>

RN 264267-01-8 CA  
 CN L-Lysine, mono[(-)-α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-56-2  
 CMF C26 H27 N O4 S


Rotation (-).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 264267-02-9 CA


CN L-Arginine, mono[(-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-56-2

CMF C26 H27 N O4 S

Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264267-03-0 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 222834-56-2

CMF C26 H27 N O4 S

Rotation (-).






CM 2

CRN 113-00-8

CMF C H5 N3



RN 264267-05-2 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-56-2

CMF C26 H27 N O4 S

Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264267-07-4 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)-α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 264267-06-3  
 CMF C26 H26 N O4 S

Rotation (-).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264267-08-5 CA  
 CN Benzenepropanoic acid, α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




● NH<sub>3</sub>

RN 264268-46-4 CA  
 CN L-Lysine, mono[α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1  
 CMF C25 H25 N O5



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 264268-47-5 CA  
 CN L-Arginine, mono[α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1  
 CMF C25 H25 N O5



CM 2

CRN 74-79-3  
 CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 264268-48-6 CA  
 CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1  
 CMF C25 H25 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264268-49-7 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-21-1

CMF C25 H25 N O5



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264268-51-1 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264268-50-0


CMF C25 H24 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O




RN 264268-52-2 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264268-60-2 CA  
 CN L-Lysine, mono[(αR)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-29-9  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).




CM 2  
 CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264268-61-3 CA  
 CN L-Arginine, mono[( $\alpha$ R)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-29-9  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2  
 CRN 74-79-3  
 CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 264268-62-4 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-29-9  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).






CM 2

CRN 113-00-8

CMF C H5 N3



RN 264268-63-5 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (R)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9

CMF C25 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264268-65-7 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (αR)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 264268-64-6  
 CMF C25 H24 N O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264268-67-9 CA  
 CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● NH<sub>3</sub>

RN 264268-74-8 CA  
 CN L-Lysine, mono[ (αS)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
 CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264268-75-9 CA

CN L-Arginine, mono[( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264268-77-1 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264268-78-2 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (S)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2

CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264268-80-6 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (αS)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 264268-79-3  
 CMF C25 H24 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264268-81-7 CA  
 CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● NH<sub>3</sub>

RN 264268-92-0 CA  
 CN L-Lysine, mono[α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-67-5  
 CMF C26 H27 N O5



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 264268-93-1 CA  
 CN L-Arginine, mono[ $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-67-5  
 CMF C26 H27 N O5



CM 2

CRN 74-79-3  
 CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264268-94-2 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-67-5  
 CMF C26 H27 N O5






CM 2

CRN 113-00-8

CMF C H5 N3




RN 264268-95-3 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-67-5

CMF C26 H27 N O5



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264268-97-5 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 264268-96-4


CMF C26 H26 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O




RN 264268-98-6 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264269-05-8 CA  
 CN L-Lysine, mono[(+)-α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-68-6  
 CMF C26 H27 N O5

Rotation (+).



CM 2  
 CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264269-06-9 CA  
CN L-Arginine, mono[(+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-68-6  
CMF C26 H27 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264269-07-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-68-6  
CMF C26 H27 N O5


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264269-08-1 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-68-6

CMF C26 H27 N O5

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264269-10-5 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 264269-09-2  
 CMF C26 H26 N O5

Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264269-11-6 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● NH<sub>3</sub>

RN 264269-18-3 CA  
 CN L-Lysine, mono[(-)-α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7  
 CMF C26 H27 N O5


Rotation (-).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264269-19-4 CA

CN L-Arginine, mono[(-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7  
CMF C26 H27 N O5


Rotation (-).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264269-20-7 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7  
CMF C26 H27 N O5

Rotation (-).






CM 2

CRN 113-00-8

CMF C H5 N3



RN 264269-21-8 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7

CMF C26 H27 N O5

Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2

HO-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>-CH<sub>2</sub>-OH

RN 264269-23-0 CA


CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)-α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264269-22-9

CMF C26 H26 N O5

Rotation (-).



CM 2

CRN 62-49-7


CMF C5 H14 N O

Me<sub>3</sub><sup>+</sup>N-CH<sub>2</sub>-CH<sub>2</sub>-OH

RN 264269-24-1 CA

CN Benzenepropanoic acid, α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




● NH<sub>3</sub>

RN 264270-09-9 CA  
 CN L-Lysine, mono[α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-23-3  
 CMF C23 H21 N O5



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 264270-11-3 CA  
 CN L-Arginine, mono[α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-23-3  
 CMF C23 H21 N O5



CM 2

CRN 74-79-3  
 CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 264270-13-5 CA  
 CN Benzenepropanoic acid, α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-23-3  
 CMF C23 H21 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264270-14-6 CA

CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-23-3


CMF C23 H21 N O5



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264270-16-8 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-15-7


CMF C23 H20 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O




RN 264270-17-9 CA

CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, monoammonium salt (9CI) (CA INDEX NAME)




RN 264270-24-8 CA  
 CN L-Lysine, mono[(+)-α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-91-5  
 CMF C23 H21 N O5

Rotation (+).



CM 2  
 CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-25-9 CA  
CN L-Arginine, mono[(+)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-91-5  
CMF C23 H21 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264270-26-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-91-5  
CMF C23 H21 N O5

Rotation (+).






CM 2

CRN 113-00-8

CMF C H5 N3



RN 264270-27-1 CA


CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-91-5

CMF C23 H21 N O5

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264270-29-3 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-28-2  
 CMF C23 H20 N O5

Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264270-30-6 CA  
 CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, monoammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




●  $\text{NH}_3$

RN 264270-37-3 CA  
CN L-Lysine, mono[(-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-94-8  
CMF C23 H21 N O5


Rotation (-).



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-39-5 CA  
CN L-Arginine, mono[(-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-94-8  
CMF C23 H21 N O5

Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264270-41-9 CA


CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-94-8


CMF C23 H21 N O5

Rotation (-).



CM 2

CRN 113-00-8  
CMF C H5 N3




RN 264270-43-1 CA  
CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-  
, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-94-8  
CMF C23 H21 N O5

Rotation (-).



CM 2

CRN 111-42-2  
CMF C4 H11 N O2




RN 264270-45-3 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-44-2  
CMF C23 H20 N O5

Rotation (-).



CM 2

CRN 62-49-7


CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264270-46-4 CA

CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, monoammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



●  $\text{NH}_3$


RN 264270-52-2 CA

CN L-Lysine, mono[ $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4

CMF C27 H29 N O5




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-53-3 CA

CN L-Arginine, mono[α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4

CMF C27 H29 N O5




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264270-54-4 CA


CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4

CMF C27 H29 N O5






CM 2

CRN 113-00-8

CMF C H5 N3




RN 264270-55-5 CA

CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4

CMF C27 H29 N O5



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264270-57-7 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-56-6


CMF C27 H28 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264270-58-8 CA

CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264270-65-7 CA  
 CN L-Lysine, mono[(+)-α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0  
 CMF C27 H29 N O5


Rotation (+).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-66-8 CA  
CN L-Arginine, mono[(+)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0  
CMF C27 H29 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264270-67-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0  
CMF C27 H29 N O5


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264270-68-0 CA


CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0

CMF C27 H29 N O5

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264270-70-4 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-69-1  
 CMF C27 H28 N O5

Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264270-71-5 CA  
 CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




●  $\text{NH}_3$

RN 264270-78-2 CA  
CN L-Lysine, mono[(-)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2  
CMF C27 H29 N O5


Rotation (-).



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-79-3 CA  
CN L-Arginine, mono[(-)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2  
CMF C27 H29 N O5

Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264270-81-7 CA


CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2

CMF C27 H29 N O5


Rotation (-).



CM 2



CRN 113-00-8  
CMF C H5 N3




RN 264270-83-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2  
CMF C27 H29 N O5

Rotation (-).



CM 2

CRN 111-42-2  
CMF C4 H11 N O2




RN 264270-85-1 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-84-0  
CMF C27 H28 N O5


Rotation (-).



CM 2

CRN 62-49-7


CMF C5 H14 N O



RN 264270-87-3 CA

CN Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 264270-99-7 CA

CN L-Lysine, mono[α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6

CMF C29 H33 N O5




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264271-01-4 CA

CN L-Arginine, mono[α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6

CMF C29 H33 N O5




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264271-03-6 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6


CMF C29 H33 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264271-05-8 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6

CMF C29 H33 N O5



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264271-08-1 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264271-07-0


CMF C29 H32 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264271-10-5 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264271-18-3 CA  
CN L-Lysine, mono[ (+)-α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3  
CMF C29 H33 N O5


Rotation (+).



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264271-19-4 CA  
CN L-Arginine, mono[(+)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3  
CMF C29 H33 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264271-20-7 CA  
CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3  
CMF C29 H33 N O5

Rotation (+).






CM 2

CRN 113-00-8

CMF C H5 N3



RN 264271-21-8 CA


CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3

CMF C29 H33 N O5

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264271-23-0 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 264271-22-9  
 CMF C29 H32 N O5

Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264271-24-1 CA  
 CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● NH<sub>3</sub>

RN 264271-31-0 CA  
 CN L-Lysine, mono[(-)-α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9  
 CMF C29 H33 N O5


Rotation (-).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 264271-32-1 CA


CN L-Arginine, mono[(-)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9

CMF C29 H33 N O5

Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264271-33-2 CA


CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9

CMF C29 H33 N O5


Rotation (-).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264271-34-3 CA


CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9

CMF C29 H33 N O5

Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264271-36-5 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 264271-35-4  
 CMF C29 H32 N O5

Rotation (-).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264271-37-6 CA  
 CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● NH<sub>3</sub>

L8 ANSWER 7 OF 10 CA COPYRIGHT 2003 ACS

135:293977 Pharmaceutical composition containing 3-[4-[2-phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxy propanoic acid. Hjorth, Thyge Borup; Knudsen, Breian (Novo Nordisk A/s, Den.). PCT Int. Appl. WO 2001074363 A1 20011011, 16 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-DK221 20010403. PRIORITY: DK 2000-557 20000404; US 2000-PV196981 20000413.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074363	A1	20011011	WO 2001-DK221	20010403
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
US 2001046990	A1	20011129	US 2001-826245	20010404

IT **264268-75-9**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmaceutical composition containing

3-[4-[2-phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxy propanoic acid)

RN 264268-75-9 CA


CN L-Arginine, mono[(αS)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2

CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



L8 ANSWER 8 OF 10 CA COPYRIGHT 2003 ACS

137:237752 Preparation of tablets and capsules containing cellulose and silica. Hjorth, Thyge Borup; Knudsen, Breian (Novo Nordisk A/S, Den.). PCT Int. Appl. WO 2002072069 A1 20020919, 20 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-DK163 20020312. PRIORITY: DK 2001-413 20010312.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072069	A1	20020919	WO 2002-DK163	20020312
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

IT 264268-75-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of tablets and capsules containing cellulose and silica)




RN 264268-75-9 CA  
CN L-Arginine, mono[( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.



L8 ANSWER 9 OF 10 CA COPYRIGHT 2003 ACS

137:201319 Preparation of  $\beta$ -aryl- $\alpha$ -oxy substituted alkylcarboxylic acids as hypolipidemic, antihyperglycemic, antiobesity, and hypocholesterolemic agents. Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Bajji, Ashok Channaveerappa; Kalchar, Shivaramayya; Paraselli, Rao Bheema; Gurram, Ranga Madhavan; Ramanujam, Rajagopalan; Chakrabarti, Ranjan (Reddy's Research Foundation, India; Reddy-Cheminor, Inc.). U.S. US 6440961 B1 20020827, 43 pp., Cont.-in-part of U.S. 6,054,453. (English). CODEN: USXXAM. APPLICATION: US 1999-257104 19990224. PRIORITY: IN 1997-MA2416 19971027; US 1998-12585 19980123.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6440961	B1	20020827	US 1999-257104	19990224
	US 6054453	A	20000425	US 1998-12585	19980123
	WO 2000050414	A1	20000831	WO 1999-IB683	19990416

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,

TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9929537	A1	20000914	AU 1999-29537	19990416
EP 1155006	A1	20011121	EP 1999-910638	19990416

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 9917155	A	20020423	BR 1999-17155	19990416
JP 2002537390	T2	20021105	JP 2000-600997	19990416
NO 2001004102	A	20011024	NO 2001-4102	20010823

IT **264266-31-1P**, L-Lysine, mono[ $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264266-33-3P**, L-Arginine, mono[ $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264266-34-4P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compound with guanidine (1:1) **264266-35-5P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compound with 2,2'-iminobis[ethanol] (1:1) **264266-37-7P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264266-38-8P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt **264266-46-8P**, L-Lysine, mono[(+)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264266-47-9P**, L-Arginine, mono[(+)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264266-48-0P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compound with guanidine (1:1) **264266-49-1P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compound with 2,2'-iminobis[ethanol] (1:1) **264266-51-5P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264266-52-6P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, ( $\alpha$ R)- **264266-60-6P**, L-Lysine, mono[(-)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264266-61-7P**, L-Arginine, mono[(-)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264266-62-8P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compound with guanidine (1:1) **264266-63-9P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compound with 2,2'-iminobis[ethanol] (1:1) **264266-65-1P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264266-66-2P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, ( $\alpha$ S)- **264266-74-2P**, L-Lysine, mono[ $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264266-75-3P**, L-Arginine, mono[ $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264266-76-4P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compound with guanidine (1:1) **264266-77-5P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compound with 2,2'-iminobis[ethanol] (1:1) **264266-79-7P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264266-80-0P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt **264266-87-7P**, L-Lysine, mono[(+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264266-88-8P**, L-Arginine, mono[(+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264266-90-2P**, Benzenepropanoic

acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compound with guanidine (1:1) **264266-91-3P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compound with 2,2'-iminobis[ethanol] (1:1) **264266-93-5P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264266-94-6P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, (+)-**264267-01-8P**, L-Lysine, mono[(-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264267-02-9P**, L-Arginine, mono[(-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] **264267-03-0P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compound with guanidine (1:1) **264267-05-2P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compound with 2,2'-iminobis[ethanol] (1:1) **264267-07-4P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264267-08-5P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, (-)-**264268-46-4P**, L-Lysine, mono[ $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264268-47-5P**, L-Arginine, mono[ $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264268-48-6P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compound with guanidine (1:1) **264268-49-7P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compound with 2,2'-iminobis[ethanol] (1:1) **264268-51-1P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264268-52-2P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt **264268-60-2P**, L-Lysine, mono[( $\alpha$ R)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264268-61-3P**, L-Arginine, mono[( $\alpha$ R)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264268-62-4P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compound with guanidine (1:1) **264268-63-5P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compound with 2,2'-iminobis[ethanol] (1:1) **264268-65-7P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with ( $\alpha$ R)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264268-67-9P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, ( $\alpha$ R)- **264268-74-8P**, L-Lysine, mono[( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264268-75-9P**, L-Arginine, mono[( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264268-77-1P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compound with guanidine (1:1) **264268-78-2P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compound with 2,2'-iminobis[ethanol] (1:1) **264268-80-6P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with ( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264268-81-7P**, Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, ( $\alpha$ S)- **264268-92-0P**, L-Lysine, mono[ $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264268-93-1P**, L-Arginine, mono[ $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264268-94-2P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compound with guanidine (1:1) **264268-95-3P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compound

with 2,2'-iminobis[ethanol] (1:1) **264268-97-5P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264268-98-6P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt **264269-05-8P**, L-Lysine, mono[(+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264269-06-9P**, L-Arginine, mono[(+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264269-07-0P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compound with guanidine (1:1) **264269-08-1P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compound with 2,2'-iminobis[ethanol] (1:1) **264269-10-5P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264269-11-6P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- **264269-18-3P**, L-Lysine, mono[(-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264269-19-4P**, L-Arginine, mono[(-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264269-20-7P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compound with guanidine (1:1) **264269-21-8P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compound with 2,2'-iminobis[ethanol] (1:1) **264269-23-0P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264269-24-1P**, Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)- **264270-09-9P**, L-Lysine, mono[ $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-11-3P**, L-Arginine, mono[ $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-13-5P**, Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compound with guanidine (1:1) **264270-14-6P**, Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compound with 2,2'-iminobis[ethanol] (1:1) **264270-16-8P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264270-17-9P**, Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, monoammonium salt **264270-24-8P**, L-Lysine, mono[(+)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-25-9P**, L-Arginine, mono[(+)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-26-0P**, Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compound with guanidine (1:1) **264270-27-1P**, Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compound with 2,2'-iminobis[ethanol] (1:1) **264270-29-3P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264270-30-6P**, Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, monoammonium salt, (+)- **264270-37-3P**, L-Lysine, mono[(-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-39-5P**, L-Arginine, mono[(-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-41-9P**, Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compound with guanidine (1:1) **264270-43-1P**, Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compound with 2,2'-iminobis[ethanol] (1:1) **264270-45-3P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264270-46-4P**, Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-

yl)ethoxy]-, monoammonium salt, (-)- **264270-52-2P**, L-Lysine, mono[α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-53-3P**, L-Arginine, mono[α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-54-4P**, Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compound with guanidine (1:1) **264270-55-5P**, Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compound with 2,2'-iminobis[ethanol] (1:1) **264270-57-7P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264270-58-8P**, Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt **264270-65-7P**, L-Lysine, mono[(+)-α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-66-8P**, L-Arginine, mono[(+)-α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-67-9P**, Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compound with guanidine (1:1) **264270-68-0P**, Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compound with 2,2'-iminobis[ethanol] (1:1) **264270-70-4P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)-α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264270-71-5P**, Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- **264270-78-2P**, L-Lysine, mono[(-)-α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-79-3P**, L-Arginine, mono[(-)-α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264270-81-7P**, Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compound with guanidine (1:1) **264270-83-9P**, Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compound with 2,2'-iminobis[ethanol] (1:1) **264270-85-1P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)-α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264270-87-3P**, Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)- **264270-99-7P**, L-Lysine, mono[α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264271-01-4P**, L-Arginine, mono[α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264271-03-6P**, Benzenepropanoic acid, α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compound with guanidine (1:1) **264271-05-8P**, Benzenepropanoic acid, α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compound with 2,2'-iminobis[ethanol] (1:1) **264271-08-1P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264271-10-5P**, Benzenepropanoic acid, α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt **264271-18-3P**, L-Lysine, mono[(+)-α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264271-19-4P**, L-Arginine, mono[(+)-α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264271-20-7P**, Benzenepropanoic acid, α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compound with guanidine (1:1) **264271-21-8P**, Benzenepropanoic acid, α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compound with 2,2'-iminobis[ethanol] (1:1) **264271-23-0P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)-α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264271-24-1P**, Benzenepropanoic acid, α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- **264271-31-0P**, L-Lysine, mono[(-)-α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264271-32-1P**, L-Arginine, mono[(-)-α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] **264271-33-2P**, Benzenepropanoic

acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compound with guanidine (1:1) **264271-34-3P**, Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compound with 2,2'-iminobis[ethanol] (1:1) **264271-36-5P**, Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) **264271-37-6P**, Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)-

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of  $\beta$ -aryl- $\alpha$ -oxy substituted alkylcarboxylic acids as hypolipidemic, antihyperglycemic, antiobesity, and hypocholesterolemic agents)


RN 264266-31-1 CA

CN L-Lysine, mono[ $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5

CMF C25 H25 N O4 S




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-33-3 CA

CN L-Arginine, mono[ $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-17-5  
CMF C25 H25 N O4 S



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 264266-34-4 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-17-5  
CMF C25 H25 N O4 S



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264266-35-5 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5

CMF C25 H25 N O4 S





CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264266-37-7 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-36-6


CMF C25 H24 N O4 S



CM 2


CRN 62-49-7

CMF C5 H14 N O




RN 264266-38-8 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264266-46-8 CA  
 CN L-Lysine, mono[ (+)-α-ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-51-7  
 CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2  
 CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-47-9 CA  
CN L-Arginine, mono[(+)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7  
CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264266-48-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7  
CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264266-49-1 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7

CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264266-51-5 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-50-4  
CMF C25 H24 N O4 S

Rotation (+).




CM 2

CRN 62-49-7  
CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264266-52-6 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




●  $\text{NH}_3$

RN 264266-60-6 CA  
CN L-Lysine, mono[(-)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-61-7 CA  
CN L-Arginine, mono[(-)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264266-62-8 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9


CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 113-00-8  
CMF C H5 N3




RN 264266-63-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 111-42-2  
CMF C4 H11 N O2




RN 264266-65-1 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-64-0  
CMF C25 H24 N O4 S

Rotation (-).





CM 2

CRN 62-49-7


CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264266-66-2 CA

CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, ammonium salt, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● NH<sub>3</sub>


RN 264266-74-2 CA

CN L-Lysine, mono[α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0

CMF C26 H27 N O4 S




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-75-3 CA

CN L-Arginine, mono[α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0

CMF C26 H27 N O4 S




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264266-76-4 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0


CMF C26 H27 N O4 S



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264266-77-5 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-54-0

CMF C26 H27 N O4 S



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264266-79-7 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-78-6


CMF C26 H26 N O4 S



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264266-80-0 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264266-87-7 CA  
 CN L-Lysine, mono[(+)-α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-55-1  
 CMF C26 H27 N O4 S


Rotation (+).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264266-88-8 CA  
CN L-Arginine, mono[(+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-55-1  
CMF C26 H27 N O4 S


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264266-90-2 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-55-1  
CMF C26 H27 N O4 S


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264266-91-3 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-55-1

CMF C26 H27 N O4 S

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2



HO-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>-CH<sub>2</sub>-OH

RN 264266-93-5 CA


CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)-α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264266-92-4

CMF C26 H26 N O4 S

Rotation (+).



CM 2

CRN 62-49-7


CMF C5 H14 N O

Me<sub>3</sub><sup>+</sup>N-CH<sub>2</sub>-CH<sub>2</sub>-OH

RN 264266-94-6 CA

CN Benzenepropanoic acid, α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● NH<sub>3</sub>

RN 264267-01-8 CA  
 CN L-Lysine, mono[(-)-α-ethoxy-α-methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-56-2  
 CMF C26 H27 N O4 S


Rotation (-).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 264267-02-9 CA


CN L-Arginine, mono[(-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-56-2

CMF C26 H27 N O4 S

Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264267-03-0 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-56-2

CMF C26 H27 N O4 S


Rotation (-).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264267-05-2 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-56-2

CMF C26 H27 N O4 S

Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264267-07-4 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 264267-06-3  
 CMF C26 H26 N O4 S

Rotation (-).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264267-08-5 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




● NH<sub>3</sub>

RN 264268-46-4 CA  
 CN L-Lysine, mono[α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1  
 CMF C25 H25 N O5



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 264268-47-5 CA  
 CN L-Arginine, mono[α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1  
 CMF C25 H25 N O5



CM 2

CRN 74-79-3  
 CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 264268-48-6 CA  
 CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1  
 CMF C25 H25 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264268-49-7 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-21-1

CMF C25 H25 N O5





CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264268-51-1 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264268-50-0


CMF C25 H24 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O




RN 264268-52-2 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264268-60-2 CA  
 CN L-Lysine, mono[(αR)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-29-9  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2  
 CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264268-61-3 CA  
CN L-Arginine, mono[( $\alpha$ R)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264268-62-4 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264268-63-5 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (R)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9

CMF C25 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264268-65-7 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (αR)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 264268-64-6  
 CMF C25 H24 N O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264268-67-9 CA  
 CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



● NH<sub>3</sub>


RN 264268-74-8 CA  
 CN L-Lysine, mono[ ( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 222834-30-2  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).



CM 2  
 CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264268-75-9 CA

CN L-Arginine, mono[( $\alpha$ S)- $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264268-77-1 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264268-78-2 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (S)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2

CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2






RN 264268-80-6 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (αS)-α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 264268-79-3  
 CMF C25 H24 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264268-81-7 CA  
 CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● NH<sub>3</sub>

RN 264268-92-0 CA  
 CN L-Lysine, mono[α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-67-5  
 CMF C26 H27 N O5



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 264268-93-1 CA  
 CN L-Arginine, mono[α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-67-5  
 CMF C26 H27 N O5



CM 2

CRN 74-79-3  
 CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 264268-94-2 CA  
 CN Benzenepropanoic acid, α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-67-5  
 CMF C26 H27 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264268-95-3 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-67-5

CMF C26 H27 N O5



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264268-97-5 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 264268-96-4


CMF C26 H26 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264268-98-6 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264269-05-8 CA  
 CN L-Lysine, mono[(+)-α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-68-6  
 CMF C26 H27 N O5


Rotation (+).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264269-06-9 CA  
CN L-Arginine, mono[(+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-68-6  
CMF C26 H27 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264269-07-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-68-6  
CMF C26 H27 N O5


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264269-08-1 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-68-6

CMF C26 H27 N O5

Rotation (+).




CM 2

CRN 111-42-2

CMF C4 H11 N O2






RN 264269-10-5 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 264269-09-2  
 CMF C26 H26 N O5

Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O



RN 264269-11-6 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● NH<sub>3</sub>

RN 264269-18-3 CA  
 CN L-Lysine, mono[(-)-α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7  
 CMF C26 H27 N O5


Rotation (-).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264269-19-4 CA

CN L-Arginine, mono[(-)- $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzeneproanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7  
CMF C26 H27 N O5


Rotation (-).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264269-20-7 CA  
CN Benzeneproanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7  
CMF C26 H27 N O5


Rotation (-).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264269-21-8 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy- $\alpha$ -methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-69-7

CMF C26 H27 N O5

Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2


HO-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>-CH<sub>2</sub>-OH

RN 264269-23-0 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)-α-ethoxy-  
α-methyl-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid  
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264269-22-9  
CMF C26 H26 N O5

Rotation (-).




CM 2

CRN 62-49-7  
CMF C5 H14 N O

Me<sub>3</sub><sup>+</sup>N-CH<sub>2</sub>-CH<sub>2</sub>-OH

RN 264269-24-1 CA  
CN Benzenepropanoic acid, α-ethoxy-α-methyl-4-[2-(10H-phenoxazin-  
10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




● NH<sub>3</sub>

RN 264270-09-9 CA  
 CN L-Lysine, mono[α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-23-3  
 CMF C23 H21 N O5



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 264270-11-3 CA  
 CN L-Arginine, mono[α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1


CRN 222834-23-3  
 CMF C23 H21 N O5



CM 2

CRN 74-79-3  
 CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 264270-13-5 CA  
 CN Benzenepropanoic acid, α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-23-3  
 CMF C23 H21 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264270-14-6 CA

CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-23-3

CMF C23 H21 N O5





CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264270-16-8 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-15-7


CMF C23 H20 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264270-17-9 CA

CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, monoammonium salt (9CI) (CA INDEX NAME)




RN 264270-24-8 CA  
 CN L-Lysine, mono[ (+)-α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-91-5  
 CMF C23 H21 N O5


Rotation (+).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-25-9 CA  
CN L-Arginine, mono[ (+)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-91-5  
CMF C23 H21 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264270-26-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-91-5  
CMF C23 H21 N O5


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264270-27-1 CA


CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-91-5

CMF C23 H21 N O5

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264270-29-3 CA  
 CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-28-2  
 CMF C23 H20 N O5

Rotation (+).




CM 2

CRN 62-49-7  
 CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264270-30-6 CA  
 CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, monoammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




●  $\text{NH}_3$

RN 264270-37-3 CA  
CN L-Lysine, mono[(-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-94-8  
CMF C23 H21 N O5


Rotation (-).



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-39-5 CA  
CN L-Arginine, mono[(-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-94-8  
CMF C23 H21 N O5

Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264270-41-9 CA


CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-94-8


CMF C23 H21 N O5

Rotation (-).



CM 2

CRN 113-00-8  
CMF C H5 N3




RN 264270-43-1 CA  
CN Benzenepropanoic acid,  $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-  
, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-94-8  
CMF C23 H21 N O5

Rotation (-).



CM 2

CRN 111-42-2  
CMF C4 H11 N O2




RN 264270-45-3 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-44-2  
CMF C23 H20 N O5

Rotation (-).






CM 2

CRN 62-49-7


CMF C5 H14 N O



RN 264270-46-4 CA

CN Benzenepropanoic acid, α-hydroxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, monoammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● NH<sub>3</sub>


RN 264270-52-2 CA

CN L-Lysine, mono[α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4

CMF C27 H29 N O5




CM 2<sup>u</sup>

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-53-3 CA

CN L-Arginine, mono[α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4

CMF C27 H29 N O5




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264270-54-4 CA

CN Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4


CMF C27 H29 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264270-55-5 CA

CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-24-4

CMF C27 H29 N O5



CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264270-57-7 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-56-6


CMF C27 H28 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264270-58-8 CA

CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264270-65-7 CA  
 CN L-Lysine, mono[(+)-α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0  
 CMF C27 H29 N O5


Rotation (+).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-66-8 CA  
CN L-Arginine, mono[(+)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0  
CMF C27 H29 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264270-67-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0  
CMF C27 H29 N O5


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264270-68-0 CA


CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-96-0

CMF C27 H29 N O5

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2






RN 264270-70-4 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-69-1  
CMF C27 H28 N O5

Rotation (+).




CM 2

CRN 62-49-7  
CMF C5 H14 N O

$Me_3^+N-CH_2-CH_2-OH$

RN 264270-71-5 CA  
CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




●  $NH_3$

RN 264270-78-2 CA  
CN L-Lysine, mono[(-)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2  
CMF C27 H29 N O5


Rotation (-).



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264270-79-3 CA  
CN L-Arginine, mono[(-)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2  
CMF C27 H29 N O5

Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 264270-81-7 CA


CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2


CMF C27 H29 N O5

Rotation (-).



CM 2

CRN 113-00-8  
CMF C H5 N3




RN 264270-83-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-98-2  
CMF C27 H29 N O5

Rotation (-).



CM 2

CRN 111-42-2  
CMF C4 H11 N O2




RN 264270-85-1 CA  
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264270-84-0  
CMF C27 H28 N O5

Rotation (-).



CM 2

CRN 62-49-7


CMF C5 H14 N O

$\text{Me}_3^+\text{N}-\text{CH}_2-\text{CH}_2-\text{OH}$

RN 264270-87-3 CA

CN Benzenepropanoic acid, α-butoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



●  $\text{NH}_3$


RN 264270-99-7 CA

CN L-Lysine, mono[α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6

CMF C29 H33 N O5




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264271-01-4 CA

CN L-Arginine, mono[α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6

CMF C29 H33 N O5




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264271-03-6 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6


CMF C29 H33 N O5



CM 2

CRN 113-00-8

CMF C H5 N3




RN 264271-05-8 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-26-6

CMF C29 H33 N O5





CM 2

CRN 111-42-2

CMF C4 H11 N O2




RN 264271-08-1 CA

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264271-07-0


CMF C29 H32 N O5



CM 2


CRN 62-49-7

CMF C5 H14 N O



RN 264271-10-5 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt (9CI) (CA INDEX NAME)




RN 264271-18-3 CA  
 CN L-Lysine, mono[(+)-α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3  
 CMF C29 H33 N O5


Rotation (+).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264271-19-4 CA  
CN L-Arginine, mono[(+)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3  
CMF C29 H33 N O5


Rotation (+).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264271-20-7 CA  
CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3  
CMF C29 H33 N O5


Rotation (+).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264271-21-8 CA


CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (+)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-99-3

CMF C29 H33 N O5

Rotation (+).



CM 2

CRN 111-42-2

CMF C4 H11 N O2



RN 264271-23-0 CA


CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (+)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264271-22-9

CMF C29 H32 N O5


Rotation (+).



CM 2

CRN 62-49-7


CMF C5 H14 N O



RN 264271-24-1 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● NH<sub>3</sub>

RN 264271-31-0 CA  
 CN L-Lysine, mono[(-)-α-(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9  
 CMF C29 H33 N O5


Rotation (-).



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 264271-32-1 CA

CN L-Arginine, mono[(-)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9  
CMF C29 H33 N O5


Rotation (-).



CM 2

CRN 74-79-3  
CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 264271-33-2 CA  
CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9  
CMF C29 H33 N O5


Rotation (-).



CM 2

CRN 113-00-8

CMF C H5 N3



RN 264271-34-3 CA


CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (-)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222835-00-9

CMF C29 H33 N O5

Rotation (-).



CM 2

CRN 111-42-2

CMF C4 H11 N O2





RN 264271-36-5 CA


CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (-)- $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 264271-35-4

CMF C29 H32 N O5


Rotation (-).



CM 2

CRN 62-49-7


CMF C5 H14 N O



RN 264271-37-6 CA

CN Benzenepropanoic acid,  $\alpha$ -(hexyloxy)-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● NH<sub>3</sub>

L8 ANSWER 10 OF 10 CA COPYRIGHT 2003 ACS

137:154935 Preparation of [(phenoxazinoalkoxy)phenyl]-2-alkoxypropanoate salts as PPAR agonists. Gaddam, Om Reddy; Mamillapalli, Ramabhadra Sarma; Chebiyyam, Prabhakar; Gutta, Madhusudan (Reddy's Research Foundation, India). PCT Int. Appl. WO 2002062772 A1 20020815, 65 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-IB341 20020205. PRIORITY: US 2001-PV267235 20010205.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062772	A1	20020815	WO 2002-IB341	20020205
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002169146	A1	20021114	US 2002-67096	20020204

IT 446019-02-9P 446019-03-0P 446019-05-2P  
 446019-06-3P 446019-07-4P 446019-09-6P  
 446019-10-9P 446019-11-0P 446019-12-1P  
 446019-13-2P 446019-14-3P 446019-16-5P  
 446019-17-6P 446019-18-7P 446019-20-1P  
 446019-21-2P 446019-22-3P 446019-23-4P  
 446019-25-6P 446019-26-7P 446019-27-8P  
 446019-28-9P 446019-29-0P 446019-30-3P  
 446019-32-5P 446019-33-6P 446019-34-7P  
 446019-35-8P 446019-37-0P 446019-38-1P  
 446019-39-2P 446019-40-5P 446019-42-7P  
 446019-43-8P 446019-44-9P 446019-45-0P  
 446019-47-2P 446019-48-3P 446019-49-4P  
 446019-50-7P 446019-52-9P 446019-53-0P

446019-54-1P 446019-55-2P 446019-57-4P  
 446019-58-5P 446019-59-6P 446019-60-9P  
 446019-62-1P 446019-63-2P 446019-64-3P  
 446019-65-4P 446019-67-6P 446019-68-7P  
 446019-69-8P 446019-70-1P 446019-71-2P  
 446019-72-3P 446019-73-4P 446019-74-5P  
 446019-75-6P 446019-76-7P 446019-77-8P  
 446019-78-9P 446019-79-0P 446019-80-3P  
 446019-81-4P 446019-82-5P 446019-84-7P  
 446019-85-8P 446019-86-9P 446019-87-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [(phenoxazinoalkoxy)phenyl]-2-alkoxypropanoate salts as PPAR agonists)

RN 446019-02-9 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with 1H-imidazole (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2

CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 288-32-4

CMF C3 H4 N2



RN 446019-03-0 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with piperazine (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2

CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-85-0

CMF C4 H10 N2



RN 446019-05-2 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (S)-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2

CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 657-24-9

CMF C4 H11 N5




RN 446019-06-3 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (S)-, compd. with 2,6-dimethylpiperazine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-30-2  
CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 108-49-6  
CMF C6 H14 N2




RN 446019-07-4 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (S)-, compd. with pyrrolidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 123-75-1

CMF C4 H9 N



RN 446019-09-6 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with benzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2

CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 100-46-9

CMF C7 H9 N


H<sub>2</sub>N-CH<sub>2</sub>-Ph

RN 446019-10-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
( $\alpha$ S)-, compd. with  $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA  
INDEX NAME)

CM 1


CRN 222834-30-2  
CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 618-36-0  
CMF C8 H11 N




RN 446019-11-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
( $\alpha$ S)-, compd. with methyl  $\alpha$ -aminobenzeneacetate (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 222834-30-2  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 26682-99-5

CMF C9 H11 N O2



RN 446019-12-1 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (S)-, compd. with phenylmethyl  $\alpha$ -aminobenzoate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2

CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 72028-76-3

CMF C15 H15 N O2






RN 446019-13-2 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (S)-, compd. with morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-30-2  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-91-8  
 CMF C4 H9 N O




RN 446019-14-3 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (S)-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
 CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 657-24-9

CMF C4 H11 N5



RN 446019-16-5 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with  $\beta$ -aminobenzeneethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9

CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 7568-92-5

CMF C8 H11 N O




RN 446019-17-6 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
 , ( $\alpha$ S)-, compd. with  $\beta$ -aminobenzenepropanol (1:1) (9CI) (CA  
 INDEX NAME)

CM 1


CRN 222834-53-9  
 CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 16088-07-6  
 CMF C9 H13 N O




RN 446019-18-7 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
 , ( $\alpha$ S)-, compd. with  $\alpha$ -methylbenzenemethanamine (1:1) (9CI)  
 (CA INDEX NAME)

CM 1

CRN 222834-53-9  
 CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 618-36-0

CMF C8 H11 N



RN 446019-20-1 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with 1H-imidazole (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9

CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 288-32-4

CMF C3 H4 N2




RN 446019-21-2 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
 , ( $\alpha$ S)-, compd. with piperazine (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-53-9  
 CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-85-0  
 CMF C4 H10 N2




RN 446019-22-3 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
 , ( $\alpha$ S)-, compd. with 2,6-dimethylpiperazine (1:1) (9CI) (CA INDEX  
 NAME)

CM 1

CRN 222834-53-9  
 CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 108-49-6

CMF C6 H14 N2



RN 446019-23-4 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with benzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9

CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 100-46-9

CMF C7 H9 N

H<sub>2</sub>N-CH<sub>2</sub>-Ph


RN 446019-25-6 CA

CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 1H-imidazole (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-21-1


CMF C25 H25 N O5



CM 2

CRN 288-32-4

CMF C3 H4 N2



RN 446019-26-7 CA


CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (αR)-, compd. with 1H-imidazole (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9

CMF C25 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 288-32-4

CMF C3 H4 N2




RN 446019-27-8 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with piperazine (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-21-1

CMF C25 H25 N O5




CM 2

CRN 110-85-0



CMF C4 H10 N2




RN 446019-28-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
( $\alpha$ R)-, compd. with piperazine (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-29-9  
CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2


CRN 110-85-0  
CMF C4 H10 N2



RN 446019-29-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX  
NAME)


CM 1

CRN 222834-21-1  
CMF C25 H25 N O5



CM 2

CRN 657-24-9  
CMF C4 H11 N5




RN 446019-30-3 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (S)-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-29-9  
CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2


CRN 657-24-9  
CMF C4 H11 N5



RN 446019-32-5 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2,6-dimethylpiperazine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 222834-21-1  
CMF C25 H25 N O5



CM 2

CRN 108-49-6  
CMF C6 H14 N2




RN 446019-33-6 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with 2,6-dimethylpiperazine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 108-49-6

CMF C6 H14 N2




RN 446019-34-7 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with pyrrolidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1

CMF C25 H25 N O5



CM 2

CRN 123-75-1  
CMF C4 H9 N




RN 446019-35-8 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
( $\alpha$ R)-, compd. with pyrrolidine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-29-9  
CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2


CRN 123-75-1  
CMF C4 H9 N



RN 446019-37-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
compd. with benzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-21-1  
CMF C25 H25 N O5



CM 2

CRN 100-46-9

CMF C7 H9 N

H<sub>2</sub>N-CH<sub>2</sub>-Ph

RN 446019-38-1 CA


CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (αR)-, compd. with benzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9

CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 100-46-9


CMF C7 H9 N

H<sub>2</sub>N-CH<sub>2</sub>-Ph

RN 446019-39-2 CA  
CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
compd. with α-methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 222834-21-1  
CMF C25 H25 N O5



CM 2

CRN 618-36-0  
CMF C8 H11 N




RN 446019-40-5 CA  
CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
(αR)-, compd. with α-methylbenzenemethanamine (1:1) (9CI) (CA  
INDEX NAME)

CM 1

CRN 222834-29-9  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 618-36-0

CMF C8 H11 N




RN 446019-42-7 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with methyl  $\alpha$ -aminobenzeneacetate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-21-1

CMF C25 H25 N O5




CM 2

CRN 26682-99-5



CMF C9 H11 N O2



RN 446019-43-8 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (R)-, compd. with methyl  $\alpha$ -aminobenzeneacetate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9

CMF C25 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 26682-99-5

CMF C9 H11 N O2




RN 446019-44-9 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with phenylmethyl  $\alpha$ -aminobenzeneacetate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1

CMF C25 H25 N O5



CM 2

CRN 72028-76-3  
CMF C15 H15 N O2




RN 446019-45-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with phenylmethyl  $\alpha$ -aminobenzeneacetate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-29-9  
CMF C25 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 72028-76-3

CMF C15 H15 N O2




RN 446019-47-2 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
compd. with morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-21-1

CMF C25 H25 N O5



CM 2

CRN 110-91-8  
CMF C4 H9 N O




RN 446019-48-3 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-,  
( $\alpha$ R)-, compd. with morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-29-9  
CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2


CRN 110-91-8  
CMF C4 H9 N O



RN 446019-49-4 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-,  
, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA  
INDEX NAME)

CM 1


CRN 222834-17-5  
CMF C25 H25 N O4 S



CM 2

CRN 657-24-9

CMF C4 H11 N5



RN 446019-50-7 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7


CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2


CRN 657-24-9  
CMF C4 H11 N5



RN 446019-52-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, compd. with  $\beta$ -aminobenzeneethanol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 222834-17-5  
CMF C25 H25 N O4 S



CM 2

CRN 7568-92-5  
CMF C8 H11 N O




RN 446019-53-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, ( $\alpha$ R)-, compd. with  $\beta$ -aminobenzeneethanol (1:1) (9CI) (CA  
INDEX NAME)

CM 1

CRN 222834-51-7  
CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 7568-92-5

CMF C8 H11 N O




RN 446019-54-1 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, compd. with  $\beta$ -aminobenzene-1-propanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5


CMF C25 H25 N O4 S



CM 2

CRN 16088-07-6

CMF C9 H13 N O




RN 446019-55-2 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
 , ( $\alpha$ R)-, compd. with  $\beta$ -aminobenzenepropanol (1:1) (9CI) (CA  
 INDEX NAME)

CM 1


CRN 222834-51-7  
 CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 16088-07-6  
 CMF C9 H13 N O




RN 446019-57-4 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
 , compd. with  $\alpha$ -methylbenzenemethanamine (1:1) (9CI) (CA INDEX  
 NAME)

CM 1

CRN 222834-17-5  
 CMF C25 H25 N O4 S






CM 2

CRN 618-36-0

CMF C8 H11 N



RN 446019-58-5 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with  $\alpha$ -methylbenzenemethanamine (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 222834-51-7

CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 618-36-0

CMF C8 H11 N




RN 446019-59-6 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with 1H-imidazole (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5


CMF C25 H25 N O4 S



CM 2

CRN 288-32-4

CMF C3 H4 N2



RN 446019-60-9 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with 1H-imidazole (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7

CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 288-32-4

CMF C3 H4 N2




RN 446019-62-1 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, compd. with piperazine (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5


CMF C25 H25 N O4 S



CM 2

CRN 110-85-0

CMF C4 H10 N2




RN 446019-63-2 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, ( $\alpha$ R)-, compd. with piperazine (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-51-7  
CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2


CRN 110-85-0  
CMF C4 H10 N2



RN 446019-64-3 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, compd. with 2,6-dimethylpiperazine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 222834-17-5  
CMF C25 H25 N O4 S



CM 2

CRN 108-49-6  
CMF C6 H14 N2




RN 446019-65-4 CA  
CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, (αR)-, compd. with 2,6-dimethylpiperazine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7  
CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 108-49-6

CMF C6 H14 N2




RN 446019-67-6 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with benzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5

CMF C25 H25 N O4 S



CM 2

CRN 100-46-9

CMF C7 H9 N

H<sub>2</sub>N-CH<sub>2</sub>-Ph

RN 446019-68-7 CA


CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with benzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-51-7

CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 100-46-9

CMF C7 H9 N

H<sub>2</sub>N-CH<sub>2</sub>-Ph


RN 446019-69-8 CA

CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-21-1


CMF C25 H25 N O5



CM 2

CRN 101-83-7

CMF C12 H23 N




RN 446019-70-1 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (R)-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-29-9  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 101-83-7  
 CMF C12 H23 N




RN 446019-71-2 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (S)-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).






CM 2

CRN 101-83-7

CMF C12 H23 N




RN 446019-72-3 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5


CMF C25 H25 N O4 S



CM 2

CRN 101-83-7

CMF C12 H23 N




RN 446019-73-4 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-51-7  
 CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 101-83-7  
 CMF C12 H23 N




RN 446019-74-5 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
 CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 101-83-7

CMF C12 H23 N




RN 446019-75-6 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with hydrazinecarboximidamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-21-1


CMF C25 H25 N O5



CM 2

CRN 79-17-4

CMF C H6 N4




RN 446019-76-7 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with hydrazinecarboximidamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-29-9  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 79-17-4  
 CMF C H6 N4




RN 446019-77-8 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with hydrazinecarboximidamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
 CMF C25 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 79-17-4

CMF C H6 N4




RN 446019-78-9 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-  
, compd. with hydrazinecarboximidamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-17-5


CMF C25 H25 N O4 S



CM 2

CRN 79-17-4

CMF C H6 N4




RN 446019-79-0 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with hydrazinecarboximidamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-51-7  
 CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 79-17-4  
 CMF C H6 N4




RN 446019-80-3 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with hydrazinecarboximidamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
 CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 79-17-4

CMF C H6 N4




RN 446019-81-4 CA

CN Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-21-1


CMF C25 H25 N O5



CM 2

CRN 75-64-9

CMF C4 H11 N




RN 446019-82-5 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (R)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-29-9  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 75-64-9  
 CMF C4 H11 N




RN 446019-84-7 CA  
 CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (S)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-30-2  
 CMF C25 H25 N O5

Absolute stereochemistry. Rotation (-).






CM 2

CRN 75-64-9

CMF C4 H11 N




RN 446019-85-8 CA

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-17-5

CMF C25 H25 N O4 S



CM 2

CRN 75-64-9  
CMF C4 H11 N




RN 446019-86-9 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ R)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 222834-51-7  
CMF C25 H25 N O4 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 75-64-9  
CMF C4 H11 N




RN 446019-87-0 CA  
CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[2-(10H-phenothiazin-10-yl)ethoxy]-, ( $\alpha$ S)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 222834-53-9  
CMF C25 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:.

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

39.80

188.96

STN INTERNATIONAL LOGOFF AT 09:57:06 ON 03 FEB 2003